Health Policy · 2018 · 35 citations · 5 references
PharmacyPharmaceutical PolicyPharmacoeconomicsHealth InsurancePharmaceutical RegulationPricing StrategyHealthcare PricingPharmaceutical EconomicsPharmaceutical FinancingPharmaceutical MarketingPrice NegotiationPricing For New ProductsAccessCo-creation With StakeholdersDrug Price TransparencyMedicine Pricing PolicyMedicines Pricing PolicyPharmaceutical Pricing StrategyStakeholder AttitudesWeb Survey Design
BACKGROUND: Innovative pricing agreements for medicines have been used in European markets for more than 20 years, and offer an opportunity for payers and pharmaceutical companies to align on value, optimise speed to patients, and share risk. Developing successful agreements requires alignment between key stakeholders, yet there is a lack of summative data on how current innovative agreements are used in the real-world (e.g. the level of realised access to medicines, and rebates and discounts, which are often non-transparent). METHODS: This research used a web-based survey of payer stakeholders to determine what kinds of innovative agreements are currently used, anticipated future usage, attitudes, and drivers of adoption. Participants included national and regional payers (or former payers) and hospital-level decision makers. RESULTS: Sixty-six payers completed the survey. Respondents expected that the use of innovative pricing agreements will remain the same or increase in the future. Overall, they felt there is a positive attitude towards new schemes, and that innovative agreements are likely to be used when they reduce total costs or reduce uncertainty. CONCLUSIONS: Given payer expectations, pharmaceutical companies should continue to take a role in ensuring that they have sufficient capacity to support payers in the design and implementation of innovative pricing agreements.
5
Louis P. Garrison, Adrian Towse, Andrew Briggs et al. · Value in Health · 2013 · 306 citations
Managed entry agreements for pharmaceuticals: the European experience
Alessandra Ferrario, Panos Kanavos · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · 2013 · 171 citations · Full text
Pharmacy, Pharmaceutical Policy, Pharmaceutical Regulation +5
Access with Evidence Development Schemes
Christopher McCabe, Tania Stafinski, Richard Edlin et al. · PharmacoEconomics · 2010 · 87 citations
Access with Evidence Development in the UK
Andrew Briggs, Karen Ritchie, Elisabeth Fenwick et al. · PharmacoEconomics · 2010 · 40 citations